WCN26-8413 SYNERGISTIC RENOPROTECTION WITH FINERENONE, DAPAGLIFLOZIN, AND TELMISARTAN IN DIABETIC KIDNEY DISEASE: REAL-WORLD EVIDENCE FROM SOUTH ASIA

Read full text Summarise with VIRAT
Authors: Shubham Dubey, Pranjal Kashiv, Mohit M. Kurundwadkar, Kapil Sejpal, Vijay Jeyachandran, Twinkle Pawar, Sushrut Gupta, Sunny Malde, Charulata P Bawankule, Amit S Pasari, Manish Balwani
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Diabetic kidney disease (DKD) remains a leading cause of end-stage renal disease, with residual proteinuria driving progression despite optimized renin–angiotensin–aldosterone system (RAAS) blockade and sodium–glucose co-transporter-2 inhibitor (SGLT2i) therapy. Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), provides additional anti-inflammatory and antifibrotic benefit, yet real-world data on its concurrent use with SGLT2 inhibitors in South Asian populations are limited.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Acute Kidney Injury Research Diabetes Treatment and Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104649–104649
Publication date
25 March 2026
Language
EN